Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP - PubMed (original) (raw)
Review
. 2004 Oct;318(1):215-24.
doi: 10.1007/s00441-004-0938-y. Epub 2004 Jul 28.
Affiliations
- PMID: 15503155
- DOI: 10.1007/s00441-004-0938-y
Review
Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP
Andreas Schober. Cell Tissue Res. 2004 Oct.
Abstract
Neurological disorders in humans can be modeled in animals using standardized procedures that recreate specific pathogenic events and their behavioral outcomes. The development of animal models of Parkinson's disease (PD) is important to test new neuroprotective agents and strategies. Such animal models of PD have to mimic, at least partially, a Parkinson-like pathology and should reproduce specific features of the human disease. PD is characterized by massive degeneration of dopaminergic neurons in the substantia nigra, the loss of striatal dopaminergic fibers and a dramatic reduction of the striatal dopamine levels. The formation of cytoplasmic inclusion bodies (Lewy bodies) in surviving dopaminergic neurons represents the most important neuropathological feature of PD. Furthermore, the massive striatal dopamine deficiency causes easily detectable motor deficits in PD patients, including bradykinesia, rigidity, and resting tremor, which are the cardinal symptoms of PD. Over the years, a broad variety of experimental models of PD were developed and applied in diverse species. This review focuses on the two most common "classical" toxin-induced PD models, the 6-hydroxy-dopamine (6-OHDA model) and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model. Both neurotoxins selectively and rapidly destroy catecholaminergic neurons, whereas in humans the PD pathogenesis follows a progressive course over decades. This discrepancy reflects one important and principal point of weakness related to most animal models. This review discusses the most important properties of 6-OHDA and MPTP, their modes of administration, and critically examines advantages and limitations of selected animal models. The new genetic and environmental toxin models of PD (e.show $132#g. rotenone, paraquat, maneb) are discussed elsewhere in this "special issue."
Similar articles
- Animal models of Parkinson's disease.
Betarbet R, Sherer TB, Greenamyre JT. Betarbet R, et al. Bioessays. 2002 Apr;24(4):308-18. doi: 10.1002/bies.10067. Bioessays. 2002. PMID: 11948617 Review. - Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
Tapias V, Cannon JR, Greenamyre JT. Tapias V, et al. J Neurosci Res. 2010 Feb 1;88(2):420-7. doi: 10.1002/jnr.22201. J Neurosci Res. 2010. PMID: 19681169 - Experimental models of Parkinson's disease: insights from many models.
Tolwani RJ, Jakowec MW, Petzinger GM, Green S, Waggie K. Tolwani RJ, et al. Lab Anim Sci. 1999 Aug;49(4):363-71. Lab Anim Sci. 1999. PMID: 10480640 Review. - Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW, Bradbury KA, Schneider JS. Anderson DW, et al. Eur J Neurosci. 2006 Dec;24(11):3174-82. doi: 10.1111/j.1460-9568.2006.05192.x. Eur J Neurosci. 2006. PMID: 17156378 - Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Alvarez-Fischer D, Henze C, Strenzke C, Westrich J, Ferger B, Höglinger GU, Oertel WH, Hartmann A. Alvarez-Fischer D, et al. Exp Neurol. 2008 Mar;210(1):182-93. doi: 10.1016/j.expneurol.2007.10.012. Epub 2007 Nov 1. Exp Neurol. 2008. PMID: 18053987
Cited by
- An increase of lysosomes through EGF-triggered endocytosis attenuated zinc-mediated lysosomal membrane permeabilization and neuronal cell death.
Eom JW, Lee JY, Kwon Y, Kim YH. Eom JW, et al. Cell Death Dis. 2024 Nov 13;15(11):823. doi: 10.1038/s41419-024-07192-6. Cell Death Dis. 2024. PMID: 39537601 Free PMC article. - Human midbrain organoids: a powerful tool for advanced Parkinson's disease modeling and therapy exploration.
Cui X, Li X, Zheng H, Su Y, Zhang S, Li M, Hao X, Zhang S, Hu Z, Xia Z, Shi C, Xu Y, Mao C. Cui X, et al. NPJ Parkinsons Dis. 2024 Oct 20;10(1):189. doi: 10.1038/s41531-024-00799-8. NPJ Parkinsons Dis. 2024. PMID: 39428415 Free PMC article. Review. - Blood-brain barrier alterations and their impact on Parkinson's disease pathogenesis and therapy.
Lau K, Kotzur R, Richter F. Lau K, et al. Transl Neurodegener. 2024 Jul 29;13(1):37. doi: 10.1186/s40035-024-00430-z. Transl Neurodegener. 2024. PMID: 39075566 Free PMC article. Review. - Male mice are susceptible to brain dysfunction induced by early-life acephate exposure.
Sasaki T, Islam J, Hara K, Nochi T, Tanemura K. Sasaki T, et al. Front Neurosci. 2024 Jul 10;18:1404009. doi: 10.3389/fnins.2024.1404009. eCollection 2024. Front Neurosci. 2024. PMID: 39050668 Free PMC article. - Cortico-basal ganglia plasticity in motor learning.
Roth RH, Ding JB. Roth RH, et al. Neuron. 2024 Aug 7;112(15):2486-2502. doi: 10.1016/j.neuron.2024.06.014. Epub 2024 Jul 12. Neuron. 2024. PMID: 39002543 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources